Efficacy and safety of Russian tableted rizatriptan 10 mg in the treatment of migraine attacks in clinical practice

   Triptans are a targeted therapy for acute migraine attacks. They are recommended for the treatment of severe attacks when non-specific analgesics are not effective. Four of the seven known triptans with different efficacy and individual tolerability are registered in the Russian Federation.

   Objective: to determine in an open-label non-comparative single center study efficacy and safety of the new Russian generic tableted rizatriptan 10 mg (Relonova) in real-life clinical practice.

   Material and methods. Thirty individuals with migraine took part in the study. Patients took rizatriptan to relieve 4 migraine attacks and filled out self-observation diaries and HIT-6 questionnaire before and after therapy.

   Results. The study involved 30 patients (26 women and 4 men) with mean age of 38.7 ± 9.3 years. Duration of migraine was 19.6 ± 11.4 years, mean number of days with migraine per month was 9.5 [5.25; 16.75]. Most patients (67 %) suffered from episodic migraine and 33 % from chronic migraine; 6 patients (20 %) had migraine attacks with aura; 20 individuals (67 %) received preventive therapy. After taking Relonova medication, pain relief was observed in 86 % of attacks, and in 45 % of cases pain disappeared completely; after 24 hours, pain relief was observed in 87 % of cases, and in 68 % – absence of attacks. A significant decrease in headache intensity was observed within 30 minutes after taking the first dose; in 34 % of attacks the headache returned. Additional analgesic treatment was required in 39 % of cases. Adverse events were observed in 25 % of attacks and were mild. The majority (63 %) of the participants were able to successfully terminate 3 attacks and were responders.

   Conclusion. Relonova is an effective and safe medication for the relief of migraine attacks.

1. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol. 1991;44(11):1147-57. doi: 10.1016/0895-4356(91)90147-2

2. Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi: 10.1177/0333102412438977. Epub 2012 Mar 6.

3. Lebedeva ER, Kobzeva NR, Gilev DV, Olesen E. Analysis of the quality of diagnosis and treatment of primary headache in different social groups of the Ural Region. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):19-26. URL: https://nnp.ima-press.net/index.php/nnp/article/view/481 (In Russ.)

4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32647-8

5. Табеева ГР, Яхно НН. Мигрень. Москва: ГЭОТАР-Медиа; 2011. [Tabeeva GR, Yakhno NN. Migraine. Moscow: GEOTAR-Media; 2011 (In Russ.)].

6. Sutherland HG, Griffiths LR. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders. Headache. 2017 Apr;57(4):537-69. doi: 10.1111/head.13053. Epub 2017 Mar 8.

7. Sergeev AV, Tabeeva GR, Azimova SE. Central neuronal hyper-excitability is a predisposition to migraine. Rossiyskiy zhurnal boli. 2010;2(27):3-11 (In Russ.)

8. Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet. 2022 Feb;54(2):152-60. doi: 10.1038/s41588-021-00990-0. Epub 2022 Feb 3.

9. Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.)

10. Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: Russian experts' recommendations. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4-14. doi: 10.14412/2074-2711-2020-4-4-14 (In Russ.)

11. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine : a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. doi: 10.2165/00003495-200060060-00003

12. Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. doi: 10.2165/00003495-200262100-00007

13. Khokhlov AL, Leykin ZN. Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):68-74. doi: 10.17116/jnevro202312308168 (In Russ.)

14. Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z

15. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache. 1998 Nov-Dec;38(10):748-55. doi: 10.1046/j.1526-4610.1998.3810748.x

16. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia. 2000 Jun;20(5):455-61. doi: 10.1046/j.1468-2982.2000.00069.x

17. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1210-8. doi: 10.1212/wnl.49.5.1210

18. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology. 1997 Dec;49(6):1485-90. doi: 10.1212/wnl.49.6.1485

19. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache. 1998 Nov-Dec;38(10):737-47. doi: 10.1046/j.1526-4610.1998.3810737.x

20. Lines C, Visser WH, Vandormael K, Reines SA. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache. 1997;37:319-20.

21. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998 Apr;38(4):281-7. doi: 10.1046/j.1526-4610.1998.3804281.x

22. Dasbach EJ, Gerth WC, Pigeon J, et al. Measuring the effect of acute migraine and its treatment on paid work and productivity loss in a randomized clinical trial of rizatriptan versus placebo. Headache. 1997;37:304-5.